Requip discontinuation
Requip discontinuation
Food and Drug Administration announced the forthcoming discontinuation of all dosage strengths of ropinirole hydrochloride (Requip) tablets as well as the 2-mg extended release (Requip XL) tablets. The FDA has announced the upcoming discontinuation for Parkinson disease and restless legs syndrome treatment ropinirole hydrochloride (Requip, GlaxoSmithKline). The phase IV clinical study analyzes which people take Requip and have Withdrawal syndrome. Children and Adolescents: Requip is not recommended for use in children below 18 years of age due to a lack of data on safety and efficacy. Some people taking medicines for Parkinson's disease have developed skin cancer requip discontinuation (melanoma) Summary: Withdrawal syndrome is found among people who take Requip, especially for people who are female, 60+ old, have been taking requip discontinuation the drug for 6 - 12 months. The anticipated final date of availability to patients will be between January and May 2019, depending on the tablet strength January 4, 2019. 3 Contraindications Hypersensitivity to ropinirole or to any of the excipients listed in section 6. The discontinuation of these products was a business decision, according to the FDA notice. Requip XL is still available as 4mg, 6mg, 8mg, and 12mg. 1 Requip XL 2mg (NDC 0007-4885-13): March 2019. You may have side effects such as fever, muscle stiffness, and confusion if you stop the medication suddenly or if you change doses. Severe renal impairment (creatinine clearance. Do not stop using Requip or change your dose without first talking to your doctor. It is created by eHealthMe based on reports of 20,431 people who have side effects when taking. The FDA notice stated that these discontinuations are the result of a business decision by manufacturer GlaxoSmithKline.